ライフサイエンスコーパス: sarcopenia

1 penia, and 14.4% vs. 8.4%, p = 0.002 for pre-sarcopenia).

2 [BMI] <20 kg/m(2)) or skeletal muscle mass (sarcopenia).

3 esis (inactivity), or an alteration in both (sarcopenia).

4 related decline in muscle mass and function (sarcopenia).

5 ift to a fibrogenic phenotype, and modulates sarcopenia.

6 dystrophy, Charcot-Marie-Tooth disease, and sarcopenia.

7 t culminate in poor outcomes associated with sarcopenia.

8 ting mTORC1 as a therapeutic target to treat sarcopenia.

9 d represent a novel therapeutic approach for sarcopenia.

10 nflammation was associated with at-diagnosis sarcopenia.

11 nd therapeutic options for the management of sarcopenia.

12 nt to avoid protein calorie malnutrition and sarcopenia.

13 al muscle and plays a key role in initiating sarcopenia.

14 s (T2DM) with the risk of sarcopenia and pre-sarcopenia.

15 d with increased risks of sarcopenia and pre-sarcopenia.

16 nctional decline with ageing, culminating in sarcopenia.

17 emic loss of muscle mass and function termed sarcopenia.

18 emerging as an effective countermeasure for sarcopenia.

19 adults is a risk factor for muscle loss and sarcopenia.

20 te was used to identify SNPs associated with sarcopenia.

21 f satellite cell activity is also a cause of sarcopenia.

22 with satellite cell senescence and premature sarcopenia.

23 ondrial disease, inflammatory myopathies and sarcopenia.

24 on to myofibre homeostasis to play a part in sarcopenia.

25 ogram and might therefore reduce the risk of sarcopenia.

26 uscle recovery may contribute to age-related sarcopenia.

27 ights into therapeutic targets for combating sarcopenia.

28 ect in muscle but instead leads to premature sarcopenia.

29 ge-induced loss of muscle mass and function, sarcopenia.

30 mic inflammation are all key contributors to sarcopenia.

31 sufficient to induce molecular signatures of sarcopenia.

32 cations for treating muscular dystrophies or sarcopenia.

33 and inflammation have potential for treating sarcopenia.

34 lated and most significantly correlated with sarcopenia.

35 s in available satellite cells and premature sarcopenia.

36 pment and testing of novel interventions for sarcopenia.

37 l muscle and has been recommended to prevent sarcopenia.

38 e useful for the prevention and treatment of sarcopenia.

39 ght therefore be useful for the treatment of sarcopenia.

40 atrophy, our findings have implications for sarcopenia.

41 a suitable therapeutic target for countering sarcopenia.

42 mass (WBLM) is a heritable trait predicting sarcopenia.

43 ics of WBLM and enhance our understanding of sarcopenia.

44 tions to prevent individuals from developing sarcopenia.

45 g aging and may therefore reduce the risk of sarcopenia.

46 orbidity had higher odds of low SMD, but not sarcopenia.

47 cell number and function and contributes to sarcopenia.

48 d to predict graft survival in patients with sarcopenia.

49 ia was significantly higher in patients with sarcopenia (62.6 +/- 17.7 versus 41.4 +/- 16.1 mug/dL, P

50 teatosis (62.5% versus 12.5%, P < 0.001) and sarcopenia (84% versus 31%, P < 0.001) were more frequen

51 Treatments are lacking for sarcopenia, a debilitating age-related skeletal muscle w

52 nections between IIS, nutritional status and sarcopenia, a hallmark feature of aging in muscle.

53 pharmacological interventions available for sarcopenia, a progressive age-associated loss of muscle

54 ide an integrated molecular profile of human sarcopenia across ethnicities, demonstrating a fundament

55 obesity did not confer any greater risk than sarcopenia alone.

56 Sarcopenia, along with intramuscular lipids, is associat

57 ic pathways show potential benefit to combat sarcopenia although further research is required, partic

58 s of ACLF in the WL, while CysC >= 1.5 mg/L, sarcopenia and albumin were independent predictors of mo

59 ated skeletal muscle atrophy which occurs in sarcopenia and cachexia.

60 s conditions characterised by low LM such as sarcopenia and cachexia.

61 ets to prevent muscle wasting, in particular sarcopenia and cachexia.

62 eletal and cardiac muscle disorders, such as sarcopenia and cardiac infarction.

63 ate process that increases susceptibility to sarcopenia and cardiovascular diseases.

64 12 months were 50% and 34% in patients with sarcopenia and CysC >=1.5 mg/L.

65 Sarcopenia and frailty predicted hospital length of stay

66 ); predictive ability did not differ between sarcopenia and frailty prediction model, reflected by ch

67 Sarcopenia and frailty were quantified in 102 patients a

68 ognitive decline, cancer, metabolic disease, sarcopenia and frailty.

69 s have investigated the relationship between sarcopenia and genotype.

70 -muscle divergence in the primary drivers of sarcopenia and identify the neuromuscular junction as a

71 and regenerative capacity, which can lead to sarcopenia and increased mortality.

72 Sarcopenia and low skeletal muscle radiodensity (SMD) ha

73 CT-assessed sarcopenia and low SMD were defined according to optimal

74 Sarcopenia and low SMD were highly prevalent (42.4% and

75 casians, African Americans had lower odds of sarcopenia and low SMD.

76 idered a therapeutic approach for preventing sarcopenia and maintaining physical independence in olde

77 Cirrhosis is characterized by sarcopenia and malnutrition, leading to progressive func

78 risk regression analysis, CysC >= 1.5 mg/L, sarcopenia and MELD-Na were independent predictors of AC

79 tential therapeutic approach for age-related sarcopenia and metabolic disease.

80 molecular changes that correlated best with sarcopenia and might contribute to its pathogenesis, we

81 How sarcopenia and muscle wasting relate to such poor outcom

82 Sarcopenia and myosteatosis were also independently asso

83 Pathophysiological mechanisms relating sarcopenia and NASH may include insulin resistance (IR)

84 lore the complex inter-relationships between sarcopenia and NASH.

85 Patients with both sarcopenia and NLR of 3 or greater (vs neither) had doub

86 were 20 deaths among the 59 patients who had sarcopenia and only 7 deaths in the nonsarcopenic group.

87 tic computed tomography (CT) scans to assess sarcopenia and osteopenia as indicators of underlying fr

88 Among the 408 who survived to discharge, sarcopenia and osteopenia were associated with higher ri

89 74 were retrospectively diagnosed with both sarcopenia and osteopenia, 167 with sarcopenia only, 48

90 d loss of muscle and bone mass and resultant sarcopenia and osteopenia.

91 We examined the association between sarcopenia and post-transplant mortality in acutely ill

92 te the association of T2DM with the risks of sarcopenia and pre-sarcopenia in China.

93 The prevalence of sarcopenia and pre-sarcopenia was significantly higher i

94 2 diabetes mellitus (T2DM) with the risk of sarcopenia and pre-sarcopenia.

95 ificantly associated with increased risks of sarcopenia and pre-sarcopenia.

96 asurements are frequently used as markers of sarcopenia and predictors of health.

97 e marrow cells into old recipients prevented sarcopenia and prevented age-related change in muscle fi

98 observed heterogeneity in the prevalence of sarcopenia and sarcopenic obesity in the 10/66 settings.

99 We investigated sarcopenia and sarcopenic obesity prevalence and sociode

100 Sarcopenia and sarcopenic obesity research in low- and m

101 te cells neither accelerated nor exacerbated sarcopenia and that satellite cells did not contribute t

102 xercise is the only known strategy to combat sarcopenia and this is largely mediated through improvem

103 To determine whether sarcopenia and/or osteopenia are associated with 1-year

104 Sarcopenia and/or osteopenia, assessed via total cross-s

105 2014 were analyzed to identify patients with sarcopenia and/or osteopenia.

106 thy controls (14.8% vs. 11.2%, p = 0.035 for sarcopenia, and 14.4% vs. 8.4%, p = 0.002 for pre-sarcop

107 of cancer, cognitive decline, osteoporosis, sarcopenia, and affective disorders, are the world's big

108 l deficiencies and predispose to osteopenia, sarcopenia, and anemia.

109 Cachexia, sarcopenia, and atrophy due to inactivity are characteri

110 stic systemic inflammation with at-diagnosis sarcopenia, and determine whether these factors interact

111 as short lifespan, dwarfism, lipodystrophy, sarcopenia, and low cardiac stress tolerance.

112 igher odds (OR: 6.19; 95% CI: 4.72, 8.11) of sarcopenia, and low SMD (OR: 17.81; 95% CI: 11.73, 27.03

113 enous vasculature, greater pectoralis muscle sarcopenia, and lower all-cause mortality.

114 thora of diseases including cancer cachexia, sarcopenia, and muscular dystrophy.

115 gery independently of indicators of frailty, sarcopenia, and pulmonary function.

116 d in related conditions, such as age-related sarcopenia, and supports the hypothesis that intrinsic c

117 xide disarrays, renal interstitial fibrosis, sarcopenia, and worsening proteinuria and kidney functio

118 Systemic inflammation and sarcopenia are easily evaluated, predict mortality in ma

119 The age-related mechanisms underlying sarcopenia are largely unknown.

120 consumed at each meal as a countermeasure to sarcopenia are presented and discussed.

121 Higher levels of CysC and sarcopenia are strongly associated with the ACLF and mor

122 The mechanisms underlying sarcopenia are unclear and the development of optimal th

123 Muscle alterations (myosteatosis and sarcopenia) are frequent in cirrhosis and related to som

124 Only sarcopenia as defined by the density indices PD and SMD

125 nhibition of the mTORC1 pathway counteracted sarcopenia, as determined by observing an increase in mu

126 Sarcopenia assessed by ultrasound may be utilized as rap

127 We believe sarcopenia assessment should be considered in all patien

128 ed by ultrasound and the predictive value of sarcopenia at SICU admission for adverse outcome has not

129 as defined using the Asian Working Group for Sarcopenia (AWGS) criteria that include both muscle mass

130 These rats exhibit sarcopenia beginning at 21 months.

131 key regulator of muscle fiber atrophy during sarcopenia but may play a key role in the decline of mit

132 There are no approved therapies for sarcopenia, but the antihypertrophic myokine myostatin i

133 ORC1 inhibition may delay the progression of sarcopenia by directly and indirectly modulating multipl

134 Bedside diagnosis of sarcopenia by ultrasound predicts adverse discharge disp

135 re compared with sex-specific thresholds for sarcopenia by using chi(2) tests and used to predict 2-y

136 equence of many primary conditions including sarcopenia, cachexia, osteoporosis, HIV/AIDS, and chroni

137 Sarcopenia can be evaluated using cross-sectional image

138 Sarcopenia can be quantified by ultrasound and the predi

139 velop a premature aging phenotype, including sarcopenia, cardiomyopathy and decreased lifespan.

140 Sarcopenia, cognitive dysfunction, depression, and nutri

141 Sarcopenia combined with inflammation nearly doubled ris

142 (SNPs) in FTO significantly associated with sarcopenia (combined p-values ranging from 5.92 x 10(-12

143 logies later in life, with predisposition to sarcopenia correlating with mTORC1 hyperactivity.

144 Assessment of sarcopenia could be used to evaluate patients before hep

145 Cut-off values for sarcopenia, defined as SMI < 50 cm(2) /m(2) in male and

146 Three established sarcopenia definitions - %Skeletal Muscle Mass (%SMM), S

147 SMI definition, but none were common to both sarcopenia definitions.

148 Sex-specific thresholds for sarcopenia demonstrated that age and race bias were not

149 The prevalence of sarcopenia depends on the definition used.

150 Age-related sarcopenia describes the loss of muscle strength and oft

151 expression and suggests a mechanism by which sarcopenia develops in cirrhotic patients.

152 Sarcopenia did not impact disease-specific (P = 0.14) or

153 of skeletal muscle mass occurs during aging (sarcopenia), disease (cachexia), or inactivity (atrophy)

154 ation analysis identified gene signatures of sarcopenia distinct from gene signatures of aging.

155 accumulation is postulated to play a role on sarcopenia during aging, which is believed to be due alt

156 motor neurons plays a key role in initiating sarcopenia during aging.

157 ssociated with protein-energy wasting (PEW), sarcopenia, dynapenia, and other complications of CKD.

158 In view to preventing sarcopenia, elderly subjects should be advised to favor

159 d present an innovative approach to treating sarcopenia, frailty, and secondary muscle wasting.

160 ociated with the %SMM and SMI definitions of sarcopenia; FTO rs9939609, ESR1 rs4870044, NOS3 rs179998

161 Sarcopenia has become the focus of intense research aimi

162 olism, and muscle loss, for instance, during sarcopenia, has profound consequences.

163 rising eGFR are potentially attributable to sarcopenia, hemodilution, and other indicators of clinic

164 eatosis was observed in 24 patients (37.5%), sarcopenia in 37 (58%), and MHE in 32 (50%).

165 months; myosteatosis was detected in 68% and sarcopenia in 84% of them.

166 Increasing NLR was associated with sarcopenia in a dose-response manner (compared with NLR

167 ts increasingly rapid progression results in sarcopenia in a subset of individuals.

168 was performed to determine the mechanisms of sarcopenia in alcoholic cirrhosis and potential reversal

169 SUMMARY OF BACKGROUND DATA: Sarcopenia in cancer may confer negative outcomes, but i

170 as well as sarcomere disruption and striking sarcopenia in cardiac and skeletal muscle, a classical f

171 of T2DM with the risks of sarcopenia and pre-sarcopenia in China.

172 sues that often occurs after surgery or with sarcopenia in late-stage cancer.

173 e the assessment and clinical implication of sarcopenia in liver transplantation (LT).

174 to form the North American Working Group on Sarcopenia in Liver Transplantation to use evidence from

175 ddress these outstanding questions regarding sarcopenia in LT.

176 ribute to the development and progression of sarcopenia in older adults.

177 ss Index (SMI) and European Working Group on Sarcopenia in Older People (EWGSOP) - were used to asses

178 The prevalence of sarcopenia in our cohort ranged from 7.0% to 37.8%, depe

179 tes the best-studied technique for assessing sarcopenia in patients with cirrhosis.

180 nts, constitute the validated definition for sarcopenia in patients with cirrhosis.

181 We will discuss the impact of sarcopenia in patients with NASH and therapeutic options

182 nction, motor coordination and resistance to sarcopenia in rhesus monkeys have recently been reported

183 to study the prevalence and significance of sarcopenia in the multimodal management of locally advan

184 Sarcopenia increased (P = 0.02) from 16% at diagnosis to

185 Sarcopenia increases through multimodal therapy, is asso

186 An NLR of 3 or greater and sarcopenia independently predicted overall (hazard ratio

187 was significantly lower on those with higher sarcopenia index (-1 d for each 10 unit of sarcopenia in

188 r sarcopenia index (-1 d for each 10 unit of sarcopenia index [95% CI, -1.4 to -0.2; p = 0.006]).

189 The relationship between sarcopenia index and hospital and 90-day mortality, and

190 The correlation (r) between sarcopenia index and muscle mass was 0.62 and coefficien

191 The sarcopenia index is a fair measure for muscle mass estim

192 rpose of this study was to describe a simple sarcopenia index using routinely available renal biomark

193 Evaluation III, body surface area, and age, sarcopenia index was independently predictive of both ho

194 , and how to best incorporate the concept of sarcopenia into clinical decision making.

195 Sarcopenia is a common complication of cirrhosis and is

196 Sarcopenia is a complex multifactorial process, some of

197 Sarcopenia is a condition characterized by progressive a

198 Sarcopenia is a hallmark of functional compromise.

199 Sarcopenia is a main indicator of adverse outcomes in th

200 Recent studies have shown that sarcopenia is a novel risk factor for developing NAFLD.

201 Sarcopenia is a progressive and generalised skeletal mus

202 Sarcopenia is an established risk factor predicting surv

203 Sarcopenia is associated with a poor prognosis in the IC

204 Sarcopenia is associated with loss of independence and i

205 Sarcopenia is associated with poor prognosis and increas

206 Sarcopenia is characterized by low skeletal muscle, a co

207 Sarcopenia is defined as a progressive and generalized l

208 Irrespective of how sarcopenia is defined, both low muscle mass and poor mus

209 Sarcopenia is frequent in cirrhosis and impacts prognosi

210 ugh no consensus diagnosis has been reached, sarcopenia is increasingly defined by both loss of muscl

211 Diagnosis, treatment, and prevention of sarcopenia is likely to become part of routine clinical

212 ween the liver and skeletal muscle mediating sarcopenia is not well understood.

213 Although the etiology of sarcopenia is unknown, the correlation during aging betw

214 Skeletal muscle loss (sarcopenia) is a major clinical complication in alcoholi

215 societal burden of age-related muscle loss (sarcopenia) is increasing.

216 ted loss of muscle mass and function, termed sarcopenia, is a catastrophic process, which impacts sev

217 Loss of muscle mass and function, or sarcopenia, is a common feature of cirrhosis and contrib

218 This condition, termed sarcopenia, is a major cause of falls and of the subsequ

219 Frailty, but not sarcopenia, is associated with worse outcomes in vascula

220 Loss of muscle mass, or sarcopenia, is nearly universal in cirrhosis and adverse

221 icle is to review the current definitions of sarcopenia, its potential causes and clinical consequenc

222 ronic mTOR inhibition is not associated with sarcopenia.Keywords: CT, MR-Imaging, Pediatrics(C) RSNA,

223 The combination of inflammation and sarcopenia may be able to identify patients with early-s

224 ween SMI and clinical response suggests that sarcopenia may be generally prognostic in this setting r

225 The gene variants associated with sarcopenia may help proper counselling and interventions

226 and imaging to assess muscle mass to detect sarcopenia, may provide insight into the likelihood of t

227 erformance Battery (SPPB) and Short Portable Sarcopenia Measure (SPSM).

228 erformance Battery (SPPB) and Short Portable Sarcopenia Measure (SPSM).

229 tionnaire (Groningen Frailty Indicator), and sarcopenia measurement (L3 muscle index) can accurately

230 ncreasing prevalence of obesity, obesity and sarcopenia occur simultaneously, a condition known as sa

231 ls and in glucocorticoid-induced atrophy and sarcopenia of aging.

232 rolonged ammonia-lowering therapy to reverse sarcopenia of cirrhosis.

233 ith both sarcopenia and osteopenia, 167 with sarcopenia only, 48 with osteopenia only, and 161 with n

234 rtebral level, compared with a group with no sarcopenia or osteopenia.

235 Sarcopenia or skeletal muscle loss is a frequent, potent

236 M exhibited significantly increased risks of sarcopenia (OR = 1.37, 95% CI = 1.02-2.03) and pre-sarco

237 enia (OR = 1.37, 95% CI = 1.02-2.03) and pre-sarcopenia (OR = 1.73, 95% CI = 1.10-2.83) compared to n

238 .62; 95% CI: 7.37, 12.56), but lower odds of sarcopenia (OR: 0.59; 95% CI: 0.48, 0.71).

239 is the relationship between low muscle mass (sarcopenia) or sarcopenic obesity and cancer prognosis?

240 Sarcopenia, or skeletal muscle atrophy, is a debilitatin

241 PURPOSE OF REVIEW: Sarcopenia, or the decline of skeletal muscle tissue wit

242 f of older trauma patients in this study had sarcopenia, osteopenia, or both.

243 compared to patients without myosteatosis or sarcopenia (P < 0.001).

244 g+), or lack Pparb and concomitantly develop sarcopenia (Pparb-/-).

245 Sarcopenia predicted adverse discharge disposition (disc

246 Furthermore, sarcopenia predicted inferior patient and graft survival

247 Weight loss combined with sarcopenia presented the greatest risk of mortality.

248 Sarcopenia prevalence ranged from 12.4% (Dominican Repub

249 Older People (EWGSOP) - were used to assess sarcopenia prevalence.

250 tly associated with the presence of MHE were sarcopenia, previous overt HE, and myosteatosis.

251 Conclusion: Myosteatosis and sarcopenia, probably by reducing the handling of ammonia

252 The term sarcopenia refers to the loss of muscle mass that occurs

253 The obesity and sarcopenia related traits are significantly different be

254 re the differences between BMDs, obesity and sarcopenia related traits from different regional sites

255 ces bone mineral density (BMD), obesity, and sarcopenia related traits in other countries.

256 ion patency (providing molecular evidence of sarcopenia-related functional denervation and neuromuscu

257 Although the mechanisms underlying sarcopenia remain unclear, the skeletal muscle stem cell

258 Sarcopenia represents one of the hallmarks of all chroni

259 Individuals with sarcopenia reproducibly demonstrate a prominent transcri

260 Conclusion: The management of sarcopenia requires a multipronged approach including nu

261 al muscle function, due to injury and aging (sarcopenia), results in a significantly decreased qualit

262 Sarcopenia revealed by low muscle density correlates wit

263 At 1 year, 35% had sarcopenia, significantly associated with pre-treatment

264 th physical activity, may delay the onset of sarcopenia, slow its progression, reduce the magnitude o

265 high Groningen Frailty Indicator score, and sarcopenia strongly predicted sepsis (P = 0.001; odds ra

266 2-/- muscles exhibited features of premature sarcopenia, such as selective type II fast fiber atrophy

267 f plasma inflammatory cytokines, anemia, and sarcopenia, suggesting that cancer-associated thrombosis

268 ver ICU stay, which appeared more related to sarcopenia than fluid balance.

269 s and strength with ageing (a process termed sarcopenia) that increases the risk of functional depend

270 A key determinant of geriatric frailty is sarcopenia, the age-associated loss of skeletal muscle m

271 Molecular mechanisms underlying sarcopenia, the age-related loss of skeletal muscle mass

272 muscle mass, the optimal cut-off values for sarcopenia, the ideal timing and frequency of muscle mas

273 Sarcopenia, the loss of muscle mass and strength during

274 ar wasting conditions, including age-related sarcopenia, the mechanisms underlying cachexia remain po

275 mpare genome-wide transcriptional changes of sarcopenia versus age-matched controls in muscle biopsie

276 ty predicted higher survival rates only when sarcopenia was absent.

277 In a multivariate Cox regression model, sarcopenia was an independent predictor of higher mortal

278 Sarcopenia was assessed using the L3 muscle index utiliz

279 On multivariable analysis, preoperative sarcopenia was associated with CCI (P = 0.043), and CDC

280 Pre-sarcopenia was defined as having low skeletal muscle ind

281 Sarcopenia was defined as less than 52 cm2/m2 and less t

282 Sarcopenia was defined by computed tomography (CT) at L3

283 Sarcopenia was defined using the Asian Working Group for

284 Sarcopenia was diagnosed by ultrasound measurement of re

285 Sarcopenia was found to be a strong and independent prog

286 On multivariate analysis, sarcopenia was found to be an independent predictor of p

287 Sarcopenia was not associated with any outcomes.

288 Sarcopenia was not predictive for anastomotic leakage or

289 The prevalence of sarcopenia and pre-sarcopenia was significantly higher in T2DM patients tha

290 In MELD-adjusted analysis, sarcopenia was strongly associated with post-transplant

291 The prevalence of sarcopenia was: %SMM 14.7%, SMI 60.6% and EWGSOP 1.3%.

292 Low muscle mass (sarcopenia) was defined as fat-free mass index (fat-free

293 An NLR of 3 or greater and sarcopenia were common (1133 [46%] and 1078 [44%], respe

294 (OR) with 95% confidence intervals (CI) for sarcopenia were higher for men 2.82 (2.22-3.57) and thos

295 s and the assessed indicators of frailty and sarcopenia were not.

296 type 2 diabetes, cardiovascular disease, and sarcopenia, which are strong risk factors of falls.

297 e-related muscle wasting and weakness termed sarcopenia, which directly impacts physical autonomy and

298 studies should evaluate whether recovery of sarcopenia with nutritional management in combination wi

299 cs of emphysema, venous vascular volume, and sarcopenia with the LV epicardial volume (LV(EV)) (myoca

300 as the progression of muscular dystrophy and sarcopenia, yet the mechanisms underlying the change in